Latest developments, partnerships and scientific breakthroughs
Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.
leadXpro AG announces its involvement in a multiparty research collaboration by delivering SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
By licensing cryosparc software and upgrading of its in-house computing capacity, leadXpro enhances its ability for high resolution structure determination of membrane protein drug targets by single particle cryo-Electron Microscopy (cryo-EM)
The registration for the International Symposium on Structure Biology for Drug Discovery@SwissFEL on June 25-27, 2019 in Villigen, Switzerland is now open.
leadXpro and Sanofi collaborate for cryo-EM structure project
leadXpro determined the first protein structure at the Swiss Free Electron Laser (SwissFEL) facilities.
